15. Inclusion body myositis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02483845 (ClinicalTrials.gov) | May 2013 | 31/5/2013 | Natalizumab in Inclusion Body Myositis (IBM) | Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis | Inclusion Body Myositis (IBM) | Drug: Natalizumab | Phoenix Neurological Associates, LTD | NULL | Active, not recruiting | 21 Years | 85 Years | All | 6 | Phase 1 | United States |